摘要
目的:观察在艾灸干预下局灶节段性肾小球硬化(FSGS)大鼠肾组织中血管内皮生长因子(VEGF)及其受体(VEGFR-2)的表达。方法:102只健康雄性SD大鼠,按体质量随机分为正常组7只、假手术组7只、造模组88只。采取间隔2周2次尾静脉注射阿霉素并单侧肾切除的方法建立FSGS大鼠模型。造模成功后大鼠根据尿蛋白定量随机分为模型组、氯沙坦组、肾俞灸法(短时、中时、长时)组和膈俞灸法(短时、中时、长时)组,每组11只,各组采用相应干预。12周后运用免疫组化法检测VEGF、VEGFR-2、ET-1、AngⅡ、AT1R在肾组织的蛋白表达;硝酸还原酶法检测NO在肾组织的含量。结果:与假手术组比较,模型组VEGF、VEGFR-2、ET-1、AngⅡ、AT1R蛋白表达显著升高,NO含量显著降低(P<0.01);与模型组比较,氯沙坦组、肾俞长时组和膈俞长时组VEGF、VEGFR-2、ET-1、AngⅡ、AT1R表达降低,NO含量升高(P<0.05,P<0.01)。结论:艾灸可能通过下调VEGF及其受体VEGFR-2的蛋白表达起到保护肾组织的作用。
Objective:To observe the effects of moxibustion intervention on treating focal segmental glomerulosclerosis(FSGS) rat model by observing the expression of vascular endothelial growth factor(VEGF) and its receptor(VEGFR-2) in renal tissue.Methods:A total of 102 SD rats were randomly divided into the normal group(n=7), sham operation group(n=7) and model group(n=88).The FSGS rat model was established by tail intravenous injection of adriamycin twice a week for two times and unilateral renal resection.After making a successful model, the rats were randomly divided into model group, losartan group, Shenshu(BL23) moxibustion group(short-term, medium-term and long-term) and Geshu(BL17) moxibustion group(shortterm, medium-term and long-term), with 11 rats in each group.Rats in each group were given corresponding intervention.After 12 weeks, immunohistochemical method was used to detect the protein expression of VEGF, VEGFR-2, ET-1, Ang II and AT1 R in renal tissue; nitrate reductase method was used to measure the content of NO in renal tissue.Results:Compared with the sham operation group, the protein expressions of VEGF, VEGFR-2, ET-1, Ang II and AT1 R in the model group were significantly increased and the contents of NO were significantly decreased(P<0.01); compared with the model group, the expressions of VEGF, VEGFR-2, ET-1, Ang II and AT1 R in losartan group, long-term Shenshu(BL23) moxibustion group and long-term Geshu(BL17) moxibustion group were decreased and the contents of NO were increased(P<0.05, P<0.01).Conclusion:Moxibustion may protect the renal tissue by down-regulating the protein expression of VEGF and its receptor VEGFR-2.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2017年第2期777-781,共5页
China Journal of Traditional Chinese Medicine and Pharmacy
基金
国家自然科学基金项目(No.81302923)
上海市中医药事业发展三年行动计划项目(No.ZYSNXD-CC-ZDYJ046)~~